EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of combined immunosuppressant and hepatitis B virus antiviral use on COVID-19 vaccination in recipients of living donor liver transplantation

Ryunjin Lee, Jiwan Choi iD, Eunkyeong Lee, Jooyoung Lee iD, Jiye Kim iD, Seoon Kang, Hye-In An, Sung-Han Kim, Sung-Min Kim, Eun-Kyoung Jwa, Gil-Chun Park, Jung-Man Namgoong und 4 weitere

PeerJ · 2024

DOI: 10.7717/peerj.18651 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2024. Verfasst von Ryunjin Lee und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Convergence Medicine, Asan Medical Institute of Convergence Science and Technology (AMIST), Seoul, Republic of South Korea. Hauptthemen laut MEDLINE: Liver Transplantation, Immunosuppressive Agents, COVID-19, Antiviral Agents. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims The global pandemic caused by the highly contagious SARS-CoV-2 virus led to the emergency approval of COVID-19 vaccines to reduce rising morbidity and mortality. However, limited research exists on evaluating the impact of these vaccines on immunocompromised individuals, such as recipients of living donor liver transplantation, highlighting the need for further studies to better understand their effectiveness in this specific population.

Methods

From June 2021, we followed up on the effectiveness of the vaccine for patients taking immunosuppressive drugs after living-donor liver transplantation (LDLT). A total of 105 immunocompromised individuals participated, of which 50 patients with hepatitis B were taking antiviral drugs. Patients were assessed to analyze how the combination of immunosuppressive and antiviral drugs affected the efficacy of the BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 COVID-19 vaccines.

Results

Before and after the vaccinations, patients were monitored to establish differences between immunosuppressed patients and those additionally taking antiviral drugs. In immunocompromised patients taking antiviral drugs for hepatitis B, we confirmed that the effect of the COVID-19 vaccine was reduced when compared to immunocompromised patients. Interestingly, 23 patients (11 without and 12 additionally with hepatitis B drug administration) encountered breakthrough infections, and although there was a minor discrepancy in vaccine efficacy among the patients taking antiviral drugs for hepatitis B, it did not reach statistical significance.

Conclusions

Additional COVID-19 vaccination is recommended for patients taking immunosuppressive drugs and hepatitis B antiviral drugs after LDLT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationImmunosuppressive AgentsCOVID-19Antiviral AgentsLiving DonorsHepatitis BCOVID-19 VaccinesImmunocompromised HostSARS-CoV-2HumansMaleFemaleMiddle AgedBNT162 VaccineAdultAged2019-nCoV Vaccine mRNA-1273VaccinationChAdOx1 nCoV-19

Stichwörter der Autor:innen

Anti-viral drugCOVID-19Hepatitis B virusLiving-donor liver transplantation

Substanzen

Immunosuppressive AgentsAntiviral AgentsCOVID-19 VaccinesBNT162 Vaccine2019-nCoV Vaccine mRNA-1273ChAdOx1 nCoV-19

Autor:innen und Institutionen

  • Department of Convergence Medicine, Asan Medical Institute of Convergence Science and Technology (AMIST), Seoul, Republic of South Korea.
  • Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of South Korea.
  • Division of Hepatobiliary Surgery and Liver Transplantation, Seoul, Republic of South Korea.
  • Division of Pediatric Surgery, Department of Surgery, Asan Medical Center, University Ulsan College of Medicine, Seoul, Republic of South Korea.

ORCID-Profile: Jiwan Choi, Jooyoung Lee, Jiye Kim

Förderung

  • National Research Foundation of Korea
  • Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea

Zitieren

APA

Lee, R., Choi, J., Lee, E., Lee, J., Kim, J., Kang, S., An, H. I., Kim, S. H., Kim, S. M., Jwa, E. K., Park, G. C., Namgoong, J. M., Song, G. W., Yoon, Y. I., Tak, E., & Lee, S. G. (2024). Effects of combined immunosuppressant and hepatitis B virus antiviral use on COVID-19 vaccination in recipients of living donor liver transplantation. PeerJ. https://doi.org/10.7717/peerj.18651

Vancouver

Lee R, Choi J, Lee E, Lee J, Kim J, Kang S, et al. Effects of combined immunosuppressant and hepatitis B virus antiviral use on COVID-19 vaccination in recipients of living donor liver transplantation. PeerJ. 2024. doi:10.7717/peerj.18651

BibTeX
@article{Lee2024,
  author = {Lee, Ryunjin and Choi, Jiwan and Lee, Eunkyeong and Lee, Jooyoung and Kim, Jiye and Kang, Seoon and An, Hye-In and Kim, Sung-Han and Kim, Sung-Min and Jwa, Eun-Kyoung and Park, Gil-Chun and Namgoong, Jung-Man and Song, Gi-Won and Yoon, Young-In and Tak, Eunyoung and Lee, Sung-Gyu},
  title = {Effects of combined immunosuppressant and hepatitis B virus antiviral use on COVID-19 vaccination in recipients of living donor liver transplantation},
  journal = {PeerJ},
  year = {2024},
  doi = {10.7717/peerj.18651}
}
Kostenlos starten →